Member Info for pomander

SS- who is pumping and dumping and do you know by what means ? - HK BB's ? Only after about 4 to 10 time periods a day when trades arise I would have thought the pump and dump was somewhat transparent. Th sp action does not definitively point to day trading in my humble opinion, but clearly you are more expert than me on the HK market I guess we will soon find out.

Alq- it probably is from my experience and I think your understanding is probably right- as I said I found the translation confusing but don't have your deep and intimate initiate knowledge of the ED marketplace. Presumably Google translates years ok ? - its hard to agree any of the numbers to the headline figures in the 2017 1st half news release, so I don't think I will bother !

Bignose - I guess you meant no news !

SS - you are absolutely incorrect in your analysis. It is not day traded heavily nor is there any consistent patterns of trading . Post the UK launch there was massive volume, and circa 35-40% of RP is tightly held. Post that period average daily volume is just 9m against 1.7 billion shares in issue - I would suggest that is not heavy day trading. Generally trading is very lumpy with spikes and no action in between A thorough analysis of the share price shares will bear this out.

Thanks for that pxs- the bit that confused me is that the article indicated that Vitaros/Vitarec generated sales of €113 m for the first 6 months for Spain, but later in the article it refers to the new medicines expected to generate revenues of around 20 million in 2017 Recordati is reconfirmed as the official partner of Apricus Biosciences, a biopharmaceutical company specializing in rheumatology and urology, for the marketing of Vitaros in Europe. In fact, the distribution of "the innovative treatment of erectile dysfunction" in Portugal, Ireland and Poland, according to the same US company, was assigned to the Italian group, already responsible for managing Vivalos and Vivirec in the Spanish market. The news was positively received by Banca Akros analysts who reiterated the accumulated rating and the target price at 31.1 euros as the Spain has already brought satisfaction to the company, recording a steady growth in revenues in the first half of the year. rose by 10.2% to EUR 111.3 million, a result of which Vivirec also contributed. Deeper cooperation between the parties is positive, the broker pointed out, both strategically and economically. In fact, adding to the offering portfolio of medicines such as Vitaros / Vitarec and Fortacin, specifically for the treatment of premature ejaculation, combined with Urorec, "will allow Recordati to build an important urological franchise network and move its focus from basic necessities to a more specialized kind of care. " On the monetary front, however, due to the new medicines, which are expected to generate revenues of around 20 million in 2017 under the new industrial plan and "leave high sales volumes", the group can achieve a good economies of scale by supporting thus further operating margins. Meanwhile, Business Square rewards the Recordati stock exchange trading at 27.88 euros, up 3.22%

Oasakobe- if you really believe that, which I don't, you should not be invested here as that would mean by implication that Mr Edwards, your CEO was a crook as he would be complicit. For that reason I do not believe any of the Placees, who were clearly lined up ahead of the BARDA announcement would have sold into the post BARDA share price rise to fund their participation in the placing..

Could be institutional buying, although none yet have breached 5% disclosure threshold. Could be a stake builder with no concern about disclosure rules or indeed it maybe circumventing them by using multiple vehicles. If you buy into the commercial opportunity Fortacin offers it ticks a lot of boxes for big pharma and it is still very cheap.

Come on now Gerry, you cannot say that it is proven yet, and indeed by taking that stance you are arguing against yourself as if it were proven the share price would surely be much higher than it is today? I have always maintained that if Summ produces stella P2 DMD readouts that in my view Sarepta will most likely be a takeover target and Summ will be in a very strong position when the horse trading begins. To bring a DMD drug to market Summ needs a heavy weight partner in whatever form that collaboration that may take. The costs and the regulatory hoops to jump through,, even post P3 are immense and there will almost inevitably be issues with payers. Lets get the P2 read outs and hope they are excellent.

Do ProactiveInvestors ever publish their performance ? They seem to pump an awful lot of stocks. The sentence ''The second point relates directly to the US$522mln Sarepta agreement. Summit’s market cap is roughly half that figure, which means the American giant might be better off bidding for its smaller rival than paying up the contract in full.'' shows lack of attention to detail and a few fronts.

Interesting trading patterns over last week, long periods with no trades at all and then just sudden spikes - not in my view indicative of punters day trading and the Chinese feeding their gambling habit.

Very philosophical Ollieh but a professional fund manager would not get away with such an approach. Guessing will not produce results in the long run, no substitute for hard work and detailed research both positive and negative and then best positioning yourself. Pharma is a very difficult sector, many fall over right at the end, ask JM about Amarin, that is why I think it is essential to have a diverse portfolio of pharma stocks just as the large funds do - look at Baker Brothers, one of the most successful. They hold hundreds of stocks. I invested into the pharma bubble as a trading strategy a few years back, but whilst I can determine a potential market for a drug and crunch the numbers, assess the historical probabilities and the general market place I am not a scientist so my final analysis is always going to be compromised. Every CEO of every pharma believes he has a cure,if they stop believing that the company is finished but unfortunately only a few succeed. I really hope Summ makes it, but there is a long way to go, RP which you know about is example of problems that can arise and compared to the complexities of Summ' s programs it should be a doodle.

correction Ollieh - if 'one' comes good, and no Ple pun intended, but the 'if' is the unknown.

From memory, and that has never been my strong suit, I seem to recall it being a half decent drinking hole. Anyway if this golden cross malarkey has legs best get those Silo's ready !.

What I find a little distasteful was the highlighting of the fact that the BARDA funding was non-dilutive to shareholders when clearly this raise was already lined up and no doubt conditional upon the BARDA funding.

5.5% rise at mo on just 23m traded - this could really blow big time on some decent volume. would appear very tightly held

The share price action would seem to broadly reflect my view - it certainly does not yet reflect a game changer. Speculating that we are experiencing a year end sell off is of the more bizarre comments ever. Funnily enough, all other things being equal, most stocks tend to do rather well into the year end, but I don't suppose that is anything to do with performance and the bonus season.

I ma wondering if they maybe considering winding the company up and making final distribution. I am sure they would prefer to develop new business within a new vehicle that they had 100% ownership of. To provide no future guidance maybe a clue.

correction - that's US dollars £12m - 4.2p per share in cash

16m of cash - 283 m shares 5.65p per share in round terms.

BARDA stepping up to the plate is good and bad and there is always a smidgen of politics involved. It does unfortunately confirm to a certain extent my view that big-pharma still has little interest in the antibiotic space as it is just not as commercially attractive as other areas of drug development. I am not disputing the serious consequences that antibiotic resistance will cause if no solutions are found, indeed they could be the greatest threat facing the planet outside of Kim Jong-un and the Don. New antibiotics of course have a future and initiatives like this are needed and far more to fund their development. Securing capital/funding form any source is the major challenge for all drug developers so as far as the bigger picture this is positive.